Tobin Fisher, MD
Family Medicine · Huntsville, ALNPI 1447231014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,815 of the $33,052 with a category attached, or 72.1%. 32 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 45.0% of the total. Reporting peaked in 2019 at $15,705 and has fallen 98.3% since, to $272 in 2025. Among family medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $133.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$15K
- Sanofi-aventis U.S. LLC$9K
- Regeneron Healthcare Solutions, Inc.$6K
- Novo Nordisk$588
- Amarin Pharma, Inc.$388
- Novartis$275
- plus $2K from 26 others
What the payments were for
- Consulting fees$2,6508%
- Speaking & faculty fees$23,81572%
- Travel & lodging$1,5825%
- Food & beverage$4,99915%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 31 | $14,883 |
| Sanofi-aventis U.S. LLC | 11 | $8,723 |
| Regeneron Healthcare Solutions, Inc. | 15 | $6,213 |
| Novo Nordisk | 45 | $588 |
| Amarin Pharma, Inc. | 16 | $388 |
| Novartis | 16 | $275 |
| AbbVie(2 entities) | 22 | $264 |
| AstraZeneca | 19 | $248 |
| Lilly USA, LLC | 14 | $219 |
| Amgen | 5 | $214 |
| Johnson & Johnson | 5 | $151 |
| Chiesi USA, Inc. | 1 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $115 |
| Astellas Pharma US Inc | 5 | $87 |
| Eisai Inc. | 6 | $75 |
| Merck | 4 | $63 |
| Pfizer | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Lundbeck LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $24 |
| GSK | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,052 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $36,624 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $35,261 |
| MounjaroTirzepatide | 26 | $25,519 |
| XareltoRivaroxaban | 26 | $25,212 |
| EliquisApixaban | 35 | $24,710 |
| MyrbetriqMirabegron | 39 | $21,801 |
| FarxigaDapagliflozin Propanediol | 22 | $12,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,980 |
| Repatha SureclickEvolocumab | 19 | $10,580 |
| LinzessLinaclotide | 16 | $7,589 |
| Pregabalin | 65 | $6,585 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,732 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,910 |
| Rosuvastatin Calcium | 216 | $3,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $588 | $36,62432 claims |
| PfizerEliquis, Premarin | $56 | $26,97647 claims |
| Lilly USA, LLCMounjaro | $219 | $25,51926 claims |
| Johnson & JohnsonXarelto | $151 | $25,21226 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $21,80139 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $20 | $18,06834 claims |
| AstraZenecaFarxiga | $248 | $12,60922 claims |
| AbbVieLinzess, Synthroid | $264 | $10,25539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- David ShowersHuntsville$18K
- Christopher OhalloranHuntsville$18K
- Michael HoneywellHuntsville$17K
- Prasanna AlladaHuntsville$16K
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.